PAP
MRNA icon

Persistent Asset Partners’s Moderna MRNA Stock Holding History

Persistent Asset Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,583
Closed -$118K – 414
2025
Q3 		$118K Buy
+4,583
New +$128K 0.08% 151

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Persistent Asset Partners's MRNA Position: Q4 2025 in Review

Persistent Asset Partners sold out of Moderna (MRNA) in Q4 2025, closing a stake of 4,583 shares — an estimated $118K sold.

Persistent Asset Partners first reported a position in MRNA in Q3 2025 and held it in 1 quarter. The position peaked at $118K in Q3 2025. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Persistent Asset Partners reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • Persistent Asset Partners sold 4,583 Moderna shares in Q4 2025, an estimated $118K.
  • Persistent Asset Partners first reported a position in Moderna in Q3 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Moderna position peaked at $118K in Q3 2025.
  • 672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.